Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Allakos Inc. - Common Stock
(NQ:
ALLK
)
1.260
+0.060 (+5.04%)
Streaming Delayed Price
Updated: 10:18 AM EST, Dec 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
57,792
Open
1.210
Bid (Size)
1.260 (5)
Ask (Size)
1.270 (11)
Prev. Close
1.200
Today's Range
1.180 - 1.290
52wk Range
0.5350 - 3.360
Shares Outstanding
86,560,315
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
10 Health Care Stocks Whale Activity In Today's Session
November 05, 2024
Via
Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
October 24, 2024
Via
Benzinga
Performance
YTD
-54.00%
-54.00%
1 Month
+43.79%
+43.79%
3 Month
+131.79%
+131.79%
6 Month
+5.04%
+5.04%
1 Year
-53.83%
-53.83%
More News
Read More
12 Health Care Stocks Moving In Wednesday's After-Market Session
October 23, 2024
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
October 22, 2024
Via
Benzinga
ALLK Stock Earnings: Allakos Beats EPS for Q2 2024
August 07, 2024
Via
InvestorPlace
ALLK Stock Earnings: Allakos Meets EPS for Q1 2024
May 09, 2024
Via
InvestorPlace
ALLK Stock Earnings: Allakos Misses EPS for Q4 2023
March 14, 2024
Via
InvestorPlace
12 Health Care Stocks Moving In Friday's After-Market Session
October 11, 2024
Via
Benzinga
Allakos Announces Phase 1 Trial Results of Subcutaneous AK006 in Healthy Volunteers
October 10, 2024
From
Allakos Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Friday's Pre-Market Session
October 04, 2024
Via
Benzinga
Allakos Provides Business Update and Reports Second Quarter 2024 Financial Results
August 07, 2024
From
Allakos Inc.
Via
GlobeNewswire
Allakos Announces Positive Results from its Ongoing Phase 1 Trial of AK006 in Healthy Volunteers, with AK006 Demonstrating High Receptor Occupancy on Mast Cells and a Favorable Safety Profile
June 25, 2024
From
Allakos Inc.
Via
GlobeNewswire
Allakos Announces First Patient Dosed in Phase 1 Trial of AK006 in Chronic Spontaneous Urticaria
May 28, 2024
From
Allakos Inc.
Via
GlobeNewswire
Allakos Provides Business Update and Reports First Quarter 2024 Financial Results
May 09, 2024
From
Allakos Inc.
Via
GlobeNewswire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
May 03, 2024
Via
InvestorPlace
12 Health Care Stocks Moving In Wednesday's After-Market Session
May 01, 2024
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
April 15, 2024
Via
InvestorPlace
3 Biotech Stocks to Dump Before They Go to Zero
April 09, 2024
Via
InvestorPlace
Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
March 14, 2024
From
Allakos Inc.
Via
GlobeNewswire
Allakos Presents Preclinical Data Highlighting Inhibition of MRGPRX2-Mediated Mast Cell Activation with AK006 at AAAAI 2024
February 26, 2024
From
Allakos Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
February 14, 2024
Via
Benzinga
Allakos Announces Publication Highlighting AK006 Mast Cell Inhibition
February 12, 2024
From
Allakos Inc.
Via
GlobeNewswire
Netflix To Rally Over 13%? Here Are 10 Top Analyst Forecasts For Wednesday
January 17, 2024
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
January 17, 2024
Via
Benzinga
Gold Down 1%; PNC Financial Posts Upbeat Earnings
January 16, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.